The Most Powerful Investment Sector of the Twenty-First Century

Now is the time to invest. InvestBio believes that biotech has the potential to create unprecedented wealth for its investors, and that the market will soon be flooded with biotechnology products. Biotech pipelines are deep, and there is a large aging population with the need for new and effective drugs. And while the industry is experiencing an increasing swell in talent as well as impressive revenue growth, the Food and Drug Administration’s (FDA) drug approvals keep validating its momentum.

In its 50 years, biotechnology has produced many historical milestones, e.g.:
1953 introduction of the double helix
1966 the genetic code was cracked
1976 the first biotechnology company formed, Genentech
1982 the first biotech drug approved by FDA; human Insulin
1994 the fist breast cancer gene is discovered
2001 the complete sequence of human genome was published
2004 the FDA approved the first anti-angiogenic drug for cancer; Avastin.

Cancer patients, in particular, are benefiting from recent biotechnology developments. A decade ago there were less than a dozen oncology drugs in clinical trials, most of which were highly toxic chemotherapies. Today there are over 400 targeted biotech medicines, including cancer drugs (with minimal side effects), being tested. In 2004, four targeted cancer drugs were approved by the FDA: Avastin, Iressa, Tarceva and Ebitux. Wall Street recognized this and rewarded these biotech companies for their success. With new drugs and treatments popping up everyday, the future surely holds many more cures for patients as well as opportunities for investors.

Even though the biotech sector is an extremely volatile, it has historically outperformed the overall market. The American Stock Exchange Biotechnology Index (BTK) is an industry recognized indicator that presents the biotech sectors performance over time.

For InvestBio’s biotechnology investment products please contact *DPEC Partners.

* InvestBio does not offer any securities. InvestBio’s biotechnology investment products and services can only be obtained through DPEC Capital, Inc.

	HOW TO INVEST
	SUITABILITY & RISKS
	ARE YOU AN ACCREDITED INVESTOR?

Market Growth from 2004 to 2010: HEM hematology; ONCO, oncology; D&E, Diabetes and endocrinology; ID*, infectious diseases including HIV; AIID, Arthritis inflammation and immune disorders; CNS, central neural system; GD, genetic disorders; WH, woman's health. Others**, respiratory plus cardiovascular;
Source: Datamonitor and company-reported information.
Nature Publishing Group
Nature Biotechnology